guess who is in it ? Ha-ha-ha: BEWARE!!!!!!!!
Alan D. Schwartz Executive Chairman
Mr. Schwartz is the former CEO of The Bear Stearns Companies. During his career with Bear Stearns, he served as president and chief operating officer, as executive vice president and co-head of investment banking and in other financial management positions. He earned a B.A. in management science from Duke University in 1972. He is a member of the Duke Board of Trustees and the Fuqua School of Business Board of Visitors.
no, they are buying...everyday it was pushed down and then bought in big hand...
Trefis Analysts estimate a price of $112 for F5 Networks' stock, about 41% higher than the current market price. Application Delivery Network constitutes 48% of the Trefis price... More
That tiny profit of Netflix is hardly anything to be exited about. With less cash on hand than before and still losing money internationally, I think it is pretty worrisome.
Ha ha ha, this is really funny , read:
The Justice Department, as you’ll recall, has accused S&P (MHFI) of helping cause the 2008 financial crash by inflating its ratings of esoteric subprime-backed securities. The company’s purported motive: pleasing the investment banks that pay its fees. The rating agency’s first line of defense was that it couldn’t be held liable for its claims of integrity because no sensible investor would believe its “AAA” rubber stamp.
In July, a federal judge in Santa Ana, Calif., brusquely rejected S&P’s “mere puffery” defense. If one read between the lines of his ruling, U.S. District Judge David Carter seemed incredulous that a company that bases its reputation on independent judgment would maintain with a straight face that it’s immune from legal consequences because no one takes its judgment seriously. “If no investor believed in S&P’s objectivity,” the judge wrote, “is S&P asserting that, as a matter of law, the company’s credit ratings service added absolutely zero material value as a predictor of creditworthiness?” It seemed like something from the theater of the absurd.
He did say it:
** BIOSCRIP INC, $10.34, down 7 pct (09:46 a.m. ET)
The infused drugs provider said the U.S. government is investigating the distribution of Novartis AG's drug Exjade by Bioscrip's former specialty pharmacy division, which was divested last year. Bioscrip said the investigation is civil in nature.
Exjade treats chronic iron overload resulting from blood transfusions, and is also approved for patients who have non-transfusion-dependent thalassemia.
10B. Position Limits and Position Accountability for Security-Based Swaps and
Large Trader Reporting.
20A. Liability to Contemporaneous Traders for Insider Trading.
How does this compare to the financial meltdown caused by the Big Boys of Wall Street?